Pharosyn, a London‑based AI infrastructure startup founded in 2022 by former McKinsey consultants and data scientists, announced a €2.5 million seed round led by European venture capital firm Atomico, with participation from UK deep‑tech fund Octopus Ventures and several pharma‑focused business angels. The capital will be used to expand its platform that aggregates clinical‑trial data, payer formularies and competitor launch timelines into a single dashboard for commercial teams.

The round values the company at roughly €12 million post‑money, according to sources close to the deal. Pharosyn says its technology is already in pilot with three of the top‑10 European pharmaceutical firms—Novartis, Roche and Bayer—helping them cut time‑to‑insight from weeks to hours and improve forecast accuracy by an estimated 15 percent.

truncated